Search results for "AGENTS"

showing 10 items of 7330 documents

Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.

2007

The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patients with inoperable bowel obstruction. A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed. Five reports fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globa…

medicine.medical_specialtymedicine.drug_classPopulationOctreotideMuscarinic AntagonistsPlaceboSettore MED/42 - Igiene Generale E ApplicataOctreotidelaw.inventionRandomized controlled trialGastrointestinal AgentslawAdrenal Cortex HormonesInternal medicineNeoplasmsButylscopolammonium BromidemedicineHumansStage (cooking)educationinoperable malignant bowel obstruction treatmentGeneral Nursingeducation.field_of_studybusiness.industryqualitative systematic reviewCancermedicine.diseaseSurgeryBowel obstructionAnesthesiology and Pain Medicineinoperable malignant bowel obstruction treatment; qualitative systematic review; management of bowel obstructionCorticosteroidNeurology (clinical)businessIntestinal Obstructionmedicine.drugmanagement of bowel obstructionJournal of pain and symptom management
researchProduct

Maintenance therapy in gastro-oesophageal reflux disease.

2005

Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics. In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylori-negative or H. pylori-positive patients have not materialized, while no cases of intesti…

medicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyDrug Administration ScheduleEsomeprazoleHiatal herniaPharmacotherapyMaintenance therapyInternal medicinemedicineHumansPharmacology (medical)SurvivorsSurgical teambusiness.industryEsophageal diseaseDecision TreesHeartburnEndoscopyProton Pump Inhibitorsmedicine.diseaseAnti-Ulcer Agentsdigestive system diseasesGastroesophageal Refluxmedicine.symptombusinessmedicine.drugDrugs
researchProduct

Selective RAR agonists for acne vulgaris: A narrative review.

2019

Background Acne vulgaris is a chronic disfiguring inflammatory disease of adolescents and adults affecting up to 90% of the population around the world. The sequence of etiopathogenesis in acne is not completely understood but involves abnormalities in sebum production, follicular plugging, proliferation of propionibacterium acnes, and chronic inflammation. Aims This review aims to summarize the features of the topical selective RAR agonists in treating acne vulgaris with a special emphasis on the 4th generation topical retinoid trifarotene. Methods Studies were identified by searching electronic databases (MEDLINE and PubMed) till August 2019 and reference lists of respective articles. Onl…

medicine.medical_specialtymedicine.drug_classReceptors Retinoic AcidPopulationTretinoinDermatologyAdministration Cutaneous030207 dermatology & venereal diseases03 medical and health sciencesPropionibacterium acnesRetinoids0302 clinical medicineMaintenance therapyTazaroteneAdapaleneAcne VulgarisMedicineHumansRetinoidAdapaleneeducationAcneRandomized Controlled Trials as Topiceducation.field_of_studybiologybusiness.industryNicotinic Acidsbiology.organism_classificationmedicine.diseaseDermatologyTreatment OutcomeTolerability030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugJournal of cosmetic dermatologyREFERENCES
researchProduct

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…

2020

Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…

medicine.medical_specialtymedicine.drug_classRespiratory SystemUrologyInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratoriotomographyDry powder inhalers Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Metered dose inhalers Tomography X-ray computedinhaled corticosteroidFluticasone propionatePulmonary Disease Chronic Obstructivechemistry.chemical_compoundFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumanslong-acting muscarinic antagonistComputer SimulationGlycopyrronium bromideRespiratory systemmetered dose inhalers1102 Cardiorespiratory Medicine and HaematologyOriginal Researchx-ray computedlcsh:RC705-779COPDScience & TechnologyInhalationbusiness.industrydry powder inhalersGeneral Medicinelcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseBronchodilator AgentsDrug CombinationschemistryCorticosteroidVilanterolbusinessLife Sciences & Biomedicinelong-acting beta2 agonistmedicine.drugInternational Journal of COPD
researchProduct

Sedation During Neurocritical Care

2019

AbstractSedation is an essential therapeutic strategy in the care of neurocritical patients. Intravenous sedative agents are the most widely used, with promising alternatives (dexmedetomidine, ketamine, and volatile agents) to propofol and midazolam arising. Studies designed to evaluate superiority and avoid biases are required. A neurological awakening test is safe in most patients. Potential risks and benefits of limiting deep sedation and daily interruption of sedation in these patients remain unclear. The aim of this review was to report recent clinical evidence on sedation in this subgroup of patients, focusing on its effects on clinical prognosis.

medicine.medical_specialtymedicine.drug_classSedationCritical Care and Intensive Care Medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineKetamineDexmedetomidineIntensive care medicinebusiness.industryNeurointensive careneurointensive care unitReview articleneurological wakeup testAnesthesiology and Pain Medicineneurocritical carelcsh:AnesthesiologySedativesedative agentsMidazolamNeurology (clinical)medicine.symptombusinessPropofol030217 neurology & neurosurgerymedicine.drugJournal of Neuroanaesthesiology and Critical Care
researchProduct

Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systemati…

2017

Early improvement of depressive symptoms during the first two weeks of antidepressant treatment has been discussed to be a resilience signal predicting a later positive treatment outcome in patients with Major Depressive Disorder (MDD). However, the predictive value of early improvement varies between studies, and the use of different antidepressants may explain heterogeneous results. The objective of this review was to assess the predictive value of early improvement on later response and remission and to identify antidepressants with the highest chance of early improvement. We included 17 randomized controlled trials investigating early improvement in 14,779 adult patients with MDD compar…

medicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectMirtazapineTricyclic antidepressantPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOutcome Assessment Health CaremedicineHumansPsychiatryBiological Psychiatrymedia_commonDepressive Disorder MajorResilience Psychologicalmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisAntidepressantMajor depressive disorderPsychological resiliencePsychology030217 neurology & neurosurgerymedicine.drugJournal of psychiatric research
researchProduct

Tutorial in oral antithrombotic therapy: biology and dental implications.

2013

Objectives: Recent developments of new direct oral anticoagulants that target specific clotting factors necessitate understanding of coagulation biology. The objective of this tutorial is to offer dental professionals a review of coagulation mechanisms and the pharmacodynamics of the conventional and new oral anticoagulants. Also, we summarized the dental implications of the conventional and new anticoagulants. Method: We searched Medline using search terms “antithrombotic”, “antihemostasis” or “anticoagulation” and combined them with the search results of “dental”, “oral surgery” or “periodontal”. We restricted the results to “human” and “English”. Results: The early coagulation cascade, t…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa InhibitorOral Surgical ProceduresAdministration OralOdontologíaHemorrhage030204 cardiovascular system & hematologyOral Surgical Procedures03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsAntithromboticmedicineHumansIntensive care medicineGeneral DentistryClotting factorbusiness.industryWarfarinReview-Article030206 dentistryPerioperative:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud3. Good healthSurgerystomatognathic diseasesOtorhinolaryngologyDirect thrombin inhibitorUNESCO::CIENCIAS MÉDICASSurgeryOral SurgerybusinessFibrinolytic agentmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil.

2009

Abstract Cigarette smoke mediated oxidative stress and endothelial dysfunction are important processes in the pathogenesis of several lung disorders. In this study we evaluated the effect of PDE5 inhibition on pulmonary artery endothelial dysfunction induced by cigarette smoke in vitro . Human pulmonary artery endothelial cells (HPAEC) were incubated in the absence or presence of PDE5 inhibitor sildenafil (10 nM–1 μM), PKG agonist 8-Br-cGMP (1 mM), or the antioxidants dyphenyleneiodonium (DPI 1 μM) and N -acetylcysteine (NAC 1 mM) for 30 min. Then, cigarette smoke extract (CSE) was added for 24 h. CSE (2.5–10%)-induced ROS generation was suppressed by DPI, and partially reversed by sildenaf…

medicine.medical_specialtymedicine.drug_mechanism_of_actionSildenafilVasodilator AgentsPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeNitric OxidePolymerase Chain ReactionPiperazinesSildenafil CitrateAcetylcysteinechemistry.chemical_compoundInternal medicineSmokeparasitic diseasesTobaccomedicineHumansSulfonesEndothelial dysfunctionPhosphodiesterase inhibitorLungCells CulturedDNA PrimersbiologyBase Sequencebusiness.industrymedicine.diseaseEndothelial stem cellEndocrinologychemistryEnzyme inhibitorPurinescardiovascular systembiology.proteinEndothelium VascularbusinessPhosphodiesterase 5 inhibitorOxidative stressmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?

2020

Summary The current SARS‐CoV‐2 pandemic particularly endangers older people with pre‐existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID‐19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS‐CoV‐2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In parti…

medicine.medical_specialtymedicine.medical_treatment610 MedizinDiseaseReviewDermatologyAntiviral Agents030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChloroquine610 Medical sciencesPandemicMedicineHumansIntensive care medicineImmunosuppression Therapybusiness.industryCOVID-19HydroxychloroquineImmunosuppressionChloroquineCOVID-19 Drug TreatmentCalcineurinVaccinationDoxycyclineRituximabbusinessmedicine.drugHydroxychloroquineJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

2018

BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anticoagulants (DOACs), notably due to the lack of coagulation tests to assess the therapeutic effects. Although the literature is scarce, consisting of small case series and retrospective studies, considering the frequency of this situation the French Vascular Neurology Society and the French Study Group on Haemostasis and Thrombosis have worked on a joint position paper to provide a practical position regarding the emergency management of ischaemic …

medicine.medical_specialtymedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanAtrial FibrillationCoagulation testingMedicineHumansThrombolytic TherapyStrokeRetrospective StudiesProthrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryAnticoagulantsIdarucizumabThrombolysismedicine.diseaseDabigatranStrokeNeurologyEmergency medicineAdministration IntravenousNeurology (clinical)Blood Coagulation Testsbusiness030217 neurology & neurosurgeryPartial thromboplastin timemedicine.drugFactor Xa InhibitorsEuropean journal of neurology
researchProduct